The contract research organization said it has already used CRISPR/Cas9 editing in several customer projects and also plans to use it for internal R&D.
Researchers from both teams plan to continue to refine their findings toward creating simple PCR or other nucleic acid amplification-based assays.
The investment bank, which also set a 12-month price target of $5 for the company's shares, said it anticipates a growing footprint for the HTG EdgeSeq system.
The Center of Individualized Diagnostic aims to bring genomic-based cancer diagnostics to Saudi Arabia.
The company hopes to leverage NxGen's assets and relationships in the maternal-fetal medicine space to aid commercialization of its proteomic preterm birth test.
In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.
Scripps Research Institute investigators peer back at the RNA world.
Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.
In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.